Sero-efficacy of Vi-polysaccharide tetanus-toxoid typhoid conjugate vaccine (Typbar-TCV) by Voysey, M, Pollard, A

“…<strong>Methods</strong> Data were obtained from a previously published phase 3 randomised controlled trial comparing Vi-polysaccharide tetanus-toxoid conjugate vaccine (Typbar-TCV; Bharat Biotech Intl Ltd, India): (Vi-TT) with Vi-polysaccharide (Typbar; Bharat Biotech Intl Ltd, India): (Vi-PS) in participants aged 2- 45 years. …”

Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

“…</p> <p>In this phase III participant-observer-blind randomized controlled trial, children aged 9 months to under-16 years old, were individually randomized (1:1) to either receive the TCV (Typbar-TCV, Bharat Biotech) or a capsular group A meningococcal conjugate vaccine (MenA) as control, and were followed-up for two years.…”

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial by Shakya, M, Voysey, M, Theiss-Nyland, K, Colin-Jones, R, Pant, D, Adhikari, A, Tonks, S, Mujadidi, YF, O'Reilly, P, Mazur, O, Kelly, S, Liu, X, Maharjan, A, Dahal, A, Haque, N, Pradhan, A, Shrestha, S, Joshi, M, Smith, N, Hill, J, Clarke, J, Stockdale, L, Jones, E, Lubinda, T, Bajracharya, B, Dongol, S, Karkey, A, Baker, S, Dougan, G, Pitzer, VE, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ

“…<br><strong> Methods<br></strong> We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). …”

Immunogenicity and efficacy of conjugated and unconjugated Vi-polysaccharide vaccines in the prevention of typhoid fever by Jin, C

“…</p> <p>The findings from this study represent the first efficacy results and comprehensive assessment of humoral immunity for the only WHO prequalified TCV - Vi-TT (Typbar-TCV, Bharat Biotech). These results contributed to a change in global health policies and funding prioritisation for TCVs. …”

Investigating novel mechanisms of immunity against enteric fever by Johnson, M

“…In 2018, a Vi-tetanus toxoid conjugate vaccine (Vi-TCV), manufactured by Bharat Biotech and targeting the Vi polysaccharide capsule of S. …”

Signatures of cellular immunity after vaccination and challenge that associate with clinical outcome of Salmonella Typhi infection by Cross, D

“…Participants were randomised to receive either a single dose of Vi-TT (Bharat Biotech), Vi-PS (Sanofi Pasteur) or a control vaccine, MenACWY (GlaxoSmithKline). …”